JINYU's subsidiary has obtained the clinical trial approval for veterinary biological products
I'm LongbridgeAI, I can summarize articles.JINYU's wholly-owned subsidiary, Jinyu Baoling Biopharmaceutical Co., Ltd., has obtained the clinical trial approval for the cat infectious peritonitis mRNA vaccine issued by the Ministry of Agriculture and Rural Affairs, becoming the first company in the country to receive clinical approval for this veterinary nucleic acid vaccine. The development of this innovative vaccine lays the foundation for the company's subsequent development of veterinary nucleic acid vaccines, but the entire research and development to market cycle is relatively long and carries uncertainties
According to the Zhitong Finance APP, JINYU (600201.SH) announced that its wholly-owned subsidiary Jinyu Baoling Biopharmaceutical Co., Ltd. (referred to as "Jinyu Baoling") has received the clinical trial approval for the cat infectious peritonitis mRNA vaccine issued by the Ministry of Agriculture and Rural Affairs (Approval No.: 2025062).
The cat infectious peritonitis mRNA vaccine is a new innovative vaccine. The company has taken the lead in overcoming the challenges of antigen design and the industrialization of nucleic acid vaccines, becoming the first company in the country to obtain clinical approval for a veterinary nucleic acid vaccine for cat infectious peritonitis, laying the foundation for the company's subsequent development of veterinary nucleic acid vaccines. The entire cycle from early research and development to market sales for veterinary vaccine products is relatively long, and there are still certain uncertainties regarding project research and development progress, technical achievements, and subsequent industrial application processes